Inclisiran
Inclisiran has been studied in 109 papers since 2018: 14 trials and 34 observational studies in people, 2 in animals, 52 reviews; 95 in the past year. It is an approved medicine. The newest paper, Nov 18, 2026: “PCSK9 Inhibition in Transition: From Established Treatments to Emerging Therapeutic Approaches”.
109 papers study it99 findingsUpdated
39 new papers in 30 daysSee all 109 papers on inclisiran
At a glance
Independent labs found the same change in people. 40 independent labs in 21 countries; 51 trials, 7 about aging, 2 with no results posted.
“Inclisiran significantly reduced: LDL-C (WMD –48.99%, 95% CI: –54.29 to –43.69)”
3 of its findings point the other way.
- 40 independent labs in 21 countries
- 3 findings against
- 51 trials, 7 about aging, 2 with no results posted
- Funders: Novartis Pharma and others
- 33 of 86 findings with company ties
- 39 of 51 trials sponsored by its developers
- Human trial14
- Humans34
- Animals2
- In silico3
Studies in people
See all 11 studies of inclisiran in people11 studies gave inclisiran to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases LDL cholesterol50% reduction down: Decreases plasma PCSK9 concentration56% reduction | Treated cohort3 months | 19 peopleHypercholesterolemia | AHA Scientific Sessions 2026 abstract, Nov 2, 2026 |
down: Decreases LDL-C51% reduction (4.8 to 2.3 mmol/L) down: Decreases lipoprotein27% reduction (70 to 51 mg/dL) up: Increases liver enzyme elevation6% of patients | Trial24 months | 172 peopleBothmean 62 ± 10 yearsPatient cohorts | ESC Congress 2026 abstract, Oct 26, 2026 |
up: Increases achievement of LDL-C <55 mg/dL91.7% versus 65.0%; RR 1.41, 95% CI 1.12–1.78; p=0.02 down: Decreases treatment-emergent adverse events18.3% versus 28.0%; p=0.04 | Randomized trial5 months | 112 peopleBothmean 68 yearsOlder adults; Ischemic HFrEF on atorvastatin 80 mg and ezetimibe 10 mg | ESC Congress 2026 abstract, Oct 26, 2026 |
up: Increases LDL-C goal attainmentD90: 85.1% vs 31.0%; D360: 89.5% vs 62.2% down: Decreases need for LLT escalation12.5% vs 52.8% requiring >20 mg rosuvastatin down: Decreases muscle-related adverse events33.3% vs 60.5%; OR 0.34 | Randomized trial360 days | 1,770 peopleInclisiran-based therapy compared with individually optimized lipid-lowering therapy | ESC Congress 2026 abstract, Oct 26, 2026 |
down: Decreases low-density lipoprotein cholesterol−40.95% (95% CI: −45.67 to −36.24) up: Improves LDL-C goal attainment78.2% vs 20.3%, aOR 16.36 (95% CI 9.72 to 27.54) | Randomized trial150 days | 402 people64.2% menmean ± standard deviation age, 63.1 ± 10.7 yearsASCVD patients with LDL-C ≥70 mg/dl on statins (± ezetimibe) | European heart journal, Aug 31, 2026 |
What did studies of inclisiran find?
36Studies of inclisiran measured 36 outcomes; the most studied are LDL-C (20 studies), LDL cholesterol (14) and low-density lipoprotein cholesterol (6).
LDL-C
downin humans18downin reviews2no changein humans1−56% to −48%
20 studies
LDL-C
downin humans18downin reviews2no changein humans1−56% to −48%
Inclisiran decreases LDL-C in humans (added to statin therapy) (51% reduction (4.8 to 2.3 mmol/L)).
“Inclisiran plus statin therapy resulted in a mean LDL-C reduction of 51% (baseline 4.8 ± 0.5 → 2.3 ± 0.4 mmol/L, p<0.001)”
Human trialadded to statin therapy300 mg subcutaneously at baseline, 3 months, then every 6 months24 monthsn = 172
ESC Congress 2026 abstract
Inclisiran decreases LDL-C in humans (versus bempedoic acid at Day 150) (least squares mean -56.3% vs -15.4%; between-group difference -41.0%).
“LDL-C reduction at Day 150 was superior with inclisiran vs BPA”
Human trialversus bempedoic acid at Day 150Day 150
European heart journal
Inclisiran decreases LDL-C in humans (elevated LDL-C, low/moderate ASCVD risk, monotherapy) (-47.50%).
“inclisiran significantly reduced LDL-C vs placebo on Day 150 (least squares mean [LSM] difference: -47.50%; P < 0.0001)”
Human trialelevated LDL-C, low/moderate ASCVD risk, monotherapy150 daysn = 207
Journal of clinical lipidology
Inclisiran decreases LDL-C in humans (chronic kidney disease stage V) (< 55 mg/dL).
“After 3 and 12 months, he attained the LDL–C target of ‹ 55 mg/dL.”
Human trialchronic kidney disease stage V284 mg s.c.12 monthsn = 1
INCLISIRAN IN TWO VERY–HIGH CV RISK PATIENTS WITH ADVANCED CHRONIC KIDNEY DISEASE
European Heart Journal Supplements
Inclisiran decreases LDL-C in humans (dyslipidemia and atherosclerotic plaques in peripheral arteries) (-65% (to 1.3 [1.2; 2.9] mmol/L, p<0.01)).
“Ninety days post-initiation of inclisiran, LDL-C was reduced by 65% (to 1.3 [1.2; 2.9] mmol/L, p<0.01)”
Human trialdyslipidemia and atherosclerotic plaques in peripheral arteries90 daysn = 22
Kardiologiia
Inclisiran decreases LDL-C in humans (WMD –48.99%, 95% CI –54.29 to –43.69).
“Inclisiran significantly reduced: LDL-C (WMD –48.99%, 95% CI: –54.29 to –43.69)”
Human trial
AHA Scientific Sessions 2025 abstract
Inclisiran decreases LDL-C in humans (−50.4% vs 0.2%, P<0.001).
“LDLleast C least squares mean percentage change from baseline at Day 90 was significantly greater with inclisiran + usual care vs usual care (LLT: −50.4% vs 0.2%; no LLT: −46.2% vs 5.5%; both P<0.001)”
Human trialwith usual care in participants with recent acute coronary syndrome receiving index lipid-lowering therapy300 mg (284 mg inclisiran equivalent) on Days 0, 90, and 270Day 90
AHA Scientific Sessions 2025 abstract
Inclisiran is linked with lower LDL-C in humans (-46% (95% CI -60.8 to -33.8%)).
“Median (95% CI) LDL-C reduction from baseline to nadir was - 46% (- 60.8 to - 33.8%).”
Humansup to 3 yearsn = 109
Clinical research in cardiology : official journal of the German Cardiac Society
Inclisiran is linked with lower LDL-C in humans after six administrations over two years (72.5% reduction from baseline (3.02 to 0.83 mmol/L)).
“After two years (six drug administrations), LDL-C was reduced to 0,83 mmol/L, corresponding to a 72,5% reduction from baseline”
Humansafter six administrations over two yearssix administrationstwo yearsn = 1
Russian Journal of Cardiology
Inclisiran is linked with lower LDL-C in humans (real-world cohort at a tertiary lipid service) (mean reduction 48.4% after first dose).
“Inclisiran therapy resulted in a mean LDL-C reduction of 48.4% following the first dose, sustained over 27 months.”
Humansreal-world cohort at a tertiary lipid servicefirst dose27 monthsn = 238
Real-world efficacy of inclisiran: data from a tertiary lipid clinic
The British journal of cardiology
All 21Fewer
LDL cholesterol
downin humans13downin reviews1−50% sustained ldl-c reduction
14 studies
LDL cholesterol
downin humans13downin reviews1−50% sustained ldl-c reduction
Inclisiran decreases LDL cholesterol in humans (-49.9% to -54.7% (P < 0.001)).
“The mean (95% confidence interval) placebo-corrected percentage changes in LDL cholesterol from baseline at day 510 in patients with eGFR ≥90, 60 to <90, 45 to <60, and 15 to <45 ml/min per 1.73 m 2 were -49.9% (-53.2 to -46.6), -51.2% (-54.4 to -48.0), -54.7% (-62.5 to -47.0), and -44.7% (-57.6 to -31.8), respectively ( P < 0.001)”
Human trialsubcutaneous510 days
Inclisiran in Patients with CKD: Post Hoc Pooled Analysis of Three Phase 3 Trials
Journal of the American Society of Nephrology : JASN
Inclisiran decreases LDL cholesterol in humans (heterozygous familial hypercholesterolaemia on maximally tolerated statin treatment) (-28·5% (95% CI -35·8 to -21·3; p<0·0001)).
“with a between-group difference of -28·5% (95% CI -35·8 to -21·3; p<0·0001)”
Human trialheterozygous familial hypercholesterolaemia on maximally tolerated statin treatmentinclisiran sodium300 mgday 330n = 141
The lancet. Diabetes & endocrinology
Inclisiran is linked with lower LDL cholesterol in humans (hypercholesterolemia) (50% reduction).
“inclisiran reduced LDL-C by 50% and plasma PCSK9 by 56% at month 3.”
Humanshypercholesterolemiaplasma3 monthsn = 19
AHA Scientific Sessions 2026 abstract
Inclisiran is linked with lower LDL cholesterol in humans (high, very high or extremely high cardiovascular risk) (−47.5 ± 26.0%; 118.2 ± 48.9 to 60.3 ± 36.3 mg/dL).
“Mean LDL-C decreased from 118.2 ± 48.9 to 60.3 ± 36.3 mg/dL (−47.5 ± 26.0%; p < 0.001)”
Humanshigh, very high or extremely high cardiovascular risk15 months
Atherosclerosis plus
Inclisiran is linked with lower LDL cholesterol in humans (Routine clinical practice) (Median reductions: 48.9% at 3 months, 51.8% at 9 months, 51.2% at 15 months, and 48.0% at 21 months).
“In real-world practice, inclisiran shows sustained LDL-C reduction up to 21 months, with approximately 50% target attainment and low discontinuation rates.”
HumansRoutine clinical practiceUp to 21 months67.2% malesn = 1,428
ESC Congress 2026 abstract
Inclisiran is linked with lower LDL cholesterol in two people with HIV on stable ART, after subcutaneous dosing at Day 1 and Day 90 (80.2% and 54.6% LDL-C reduction at Month 6).
“Case 1 achieved an 80.2% LDL-C reduction to 28 mg/dL at Month 6, and Case 2 achieved a 54.6% reduction to 88 mg/dL at Month 6 as monotherapy.”
Humansin two people with HIV on stable ART, after subcutaneous dosing at Day 1 and Day 906 monthsmalesn = 2
Reports (MDPI)
Inclisiran is linked with lower LDL cholesterol in routine clinical practice (median approximately -25% to -40% across follow-up visits).
“Median LDL-C reduction ranged from approximately - 25% to - 40% across follow-up visits.”
Humansin routine clinical practicemedian follow-up 18 monthsn = 67
BMC cardiovascular disorders
Inclisiran is linked with lower LDL cholesterol in humans (−33.2% (−1.17 mmol/L), unadjusted).
“mean unadjusted LDL-C reductions were − 58.2% (–1.98 mmol/L), − 58.9% (–2.09 mmol/L), and − 33.2% (–1.17 mmol/L), respectively (p < 0.001).”
Humansn = 94
Lipids in health and disease
Inclisiran is linked with lower LDL cholesterol in humans (chronic kidney disease and chronic ischemic heart disease) (almost 50% reduction).
“After 12 months of treatment, there was almost 50% reduction in both total and LDL cholesterol values”
Humanschronic kidney disease and chronic ischemic heart disease284 mg12 monthsn = 32
Inclisiran in Chronic Kidney Disease Patients: A Real-World Experience
Cardiorenal medicine
Inclisiran decreases LDL cholesterol in humans (chronic kidney disease).
“Evolocumab, alirocumab, and inclisiran consistently lowered low-density lipoprotein cholesterol”
Reviewchronic kidney disease
Clinical therapeutics
All 14Fewer
Low-density lipoprotein cholesterol
downin humans6−60% to −50% reduction
6 studies
Low-density lipoprotein cholesterol
downin humans6−60% to −50% reduction
Inclisiran decreases low-density lipoprotein cholesterol in humans (−40.95% (95% CI: −45.67 to −36.24)).
“Inclisiran demonstrated superior efficacy vs BPA in lowering LDL-C, meeting the primary efficacy objective of the study.”
Human trial150 daysn = 402
European heart journal
Inclisiran is linked with lower low-density lipoprotein cholesterol in humans (117.4 to 45.9 mg/dL).
“The LDL-C levels decreased from 117.4 mg/dL (95% confidence interval [CI], 113.3-121.6) to 45.9 mg/dL (39.5-52.3) at 15 months.”
Humans15 months
Diagnostics (Basel, Switzerland)
Inclisiran is linked with lower low-density lipoprotein cholesterol in humans (real-world clinical practice) (-44.7% after 1st dose, -40.8% after 2nd dose).
“Median LDL-C reduction after the 1st and 2nd doses was 44.7% and 40.8%, respectively.”
Humansreal-world clinical practicen = 95
Journal of clinical lipidology
Inclisiran is linked with lower low-density lipoprotein cholesterol in humans with statin ± ezetimibe (59.5% reduction).
“At 15 months, the mean low-density lipoprotein cholesterol (LDL-C) levels decreased by 59.5% in patients receiving statin ± ezetimibe”
Humanswith statin ± ezetimibe15 months
Journal of cardiovascular medicine (Hagerstown, Md.)
Inclisiran is linked with lower low-density lipoprotein cholesterol in humans (-46.8% (95% CI 42.7-51.0)).
“Mean absolute LDL-C reduction was 66.1 (standard deviation: 45.6) mg/dl, corresponding to a 46.8% (95% confidence interval: 42.7-51.0) relative reduction”
Humans12 monthsn = 202
Cardiology and therapy
Inclisiran decreases low-density lipoprotein cholesterol in humans (approximately 50% reduction).
“Inclisiran reduced low-density lipoprotein cholesterol by approximately 50% with twice-yearly dosing”
Reviewtwice-yearly dosing
Cardiology in review
Lipoprotein
downin humans5−33% to −18%
5 studies
Lipoprotein
downin humans5−33% to −18%
Inclisiran decreases lipoprotein in humans (added to statin therapy) (27% reduction (70 to 51 mg/dL)).
“and Lp(a) reduction of 27% (baseline 70 ± 15 → 51 ± 12 mg/dL, p<0.001)”
Human trialadded to statin therapy300 mg subcutaneously at baseline, 3 months, then every 6 months24 monthsn = 172
ESC Congress 2026 abstract
Inclisiran decreases lipoprotein in humans (elevated LDL-C, low/moderate ASCVD risk, monotherapy) (-30.27%).
“inclisiran induced a significant (P < 0.0001) reduction in other atherogenic lipoproteins and lipid biomarkers (placebo-adjusted LSM difference: lipoprotein(a), -30.27%”
Human trialelevated LDL-C, low/moderate ASCVD risk, monotherapy150 daysn = 207
Journal of clinical lipidology
Inclisiran decreases lipoprotein in humans (dyslipidemia and atherosclerotic plaques in peripheral arteries) (-33%).
“and Lp(a) by 33%”
Human trialdyslipidemia and atherosclerotic plaques in peripheral arteries90 daysn = 22
Kardiologiia
Inclisiran is linked with lower lipoprotein in humans (unadjusted analyses) (-8% to -17%).
“and from -8% to -17% with inclisiran”
Humansunadjusted analyses
Atherosclerosis
Inclisiran decreases lipoprotein in humans (meta-analyses of RCTs) (18.00%).
“and inclisiran (18.00%; high certainty).”
Reviewmeta-analyses of RCTs
Drugs
Muscle-related adverse events
downin humans2OR 0.34–0.57
2 studies
Muscle-related adverse events
downin humans2OR 0.34–0.57
Inclisiran decreases muscle-related adverse events in humans among participants on no rosuvastatin (33.3% vs 60.5%; OR 0.34).
“Significantly fewer muscle-related AEs occurred with inclisiran-based therapy vs ioLLT among those on no rosuvastatin (33.3% vs 60.5%; odds ratio [OR], 0.34; 95% confidence interval [CI], 0.13–0.85)”
Human trialamong participants on no rosuvastatin360 days
Inclisiran helped more high-risk people reach cholesterol goals
ESC Congress 2026 abstract
Inclisiran decreases muscle-related adverse events in humans (hypercholesterolemia at high or very high CV risk on maximally tolerated dose of statins) (11.9% vs. 19.2%, OR 0.57 (95% CI: 0.43, 0.74)).
“Fewer participants in the inclisiran vs. SOC arm experienced a MRAE (11.9% vs. 19.2%; odds ratio=0.57; 95% CI: 0.43, 0.74).”
Human trialhypercholesterolemia at high or very high CV risk on maximally tolerated dose of statins300 mg subcutaneous360 daysn = 1,770
AHA Scientific Sessions 2025 abstract
LDL-C goal attainment
upin humans2
2 studies
LDL-C goal attainment
upin humans2
Inclisiran increases LDL-C goal attainment in humans (inclisiran-based therapy compared with individually optimized lipid-lowering therapy) (D90: 85.1% vs 31.0%; D360: 89.5% vs 62.2%).
“More participants achieved LDL-C goals with inclisiran-based therapy vs ioLLT (D90: 85.1% vs 31.0%; D360: 89.5% vs 62.2%).”
Human trialinclisiran-based therapy compared with individually optimized lipid-lowering therapy360 days
Inclisiran helped more high-risk people reach cholesterol goals
ESC Congress 2026 abstract
Inclisiran increases LDL-C goal attainment in humans (versus bempedoic acid) (78.2% vs 20.3%; adjusted odds ratio 16.36, 95% CI 9.72 to 27.54).
“with higher LDL-C goal attainment (78.2% vs 20.3%; adjusted odds ratio 16.36, 95% CI 9.72 to 27.54; descriptive p<0.0001)”
Human trialversus bempedoic acid
European heart journal
Treatment-emergent adverse events
downin humans1no changein humans1
2 studies
Treatment-emergent adverse events
downin humans1no changein humans1
Inclisiran decreases treatment-emergent adverse events in humans (Ischemic HFrEF on atorvastatin 80 mg and ezetimibe 10 mg; compared with evolocumab) (18.3% versus 28.0%; p=0.04).
“The incidence of TEAEs was lower with Inclisiran (18.3% vs. 28.0%; p=0.04), driven mainly by fewer injection-site reactions (10.5% vs. 17.0%).”
Human trialIschemic HFrEF on atorvastatin 80 mg and ezetimibe 10 mg; compared with evolocumabsiRNA284 mg5 months75% malesn = 112
ESC Congress 2026 abstract
Inclisiran showed no clear effect on treatment-emergent adverse events in humans (versus bempedoic acid) (63.1% vs 59.8%).
“comparable rates of TEAEs (63.1% vs 59.8%) and serious TEAEs (5.9% vs 7.5%)”
Human trialversus bempedoic acid
European heart journal
Adverse events
upin humans2RR 1.06
2 studies
Adverse events
upin humans2RR 1.06
Inclisiran increases adverse events in humans (RR 1.06; p=0.02).
“Total adverse events were slightly higher with inclisiran (RR 1.06; p=0.02)”
Human trial
AHA Scientific Sessions 2025 abstract
Inclisiran is linked with adverse events in humans (atherosclerotic cardiovascular disease or HeFH) (4% (24 patients)).
“AEs were reported by 24 patients (4%), of whom 12 (50%) discontinued treatment.”
Humansatherosclerotic cardiovascular disease or HeFHn = 562
Journal of clinical lipidology
Total cholesterol
downin humans2
2 studies
Total cholesterol
downin humans2
Inclisiran decreases total cholesterol in humans (dyslipidemia and atherosclerotic plaques in peripheral arteries) (-30% (p<0.01)).
“TC by 30% (p<0.01)”
Human trialdyslipidemia and atherosclerotic plaques in peripheral arteries90 daysn = 22
Kardiologiia
Inclisiran is linked with lower total cholesterol in humans (chronic kidney disease and chronic ischemic heart disease) (almost 50% reduction).
“After 12 months of treatment, there was almost 50% reduction in both total and LDL cholesterol values”
Humanschronic kidney disease and chronic ischemic heart disease284 mg12 monthsn = 32
Inclisiran in Chronic Kidney Disease Patients: A Real-World Experience
Cardiorenal medicine
Hepatic PCSK9 synthesis
downin humans1
1 study
Hepatic PCSK9 synthesis
downin humans1
Inclisiran inhibits hepatic PCSK9 synthesis in humans.
“inclisiran, a small interfering RNA (siRNA), achieves sustained suppression of hepatic PCSK9 synthesis with infrequent dosing.”
Reviewsmall interfering RNA (siRNA)liver
PCSK9 Inhibition in Transition: From Established Treatments to Emerging Therapeutic Approaches
International journal of molecular sciences
Liver enzyme elevation
upin humans1+6% patients
1 study
Liver enzyme elevation
upin humans1+6% patients
Inclisiran increases liver enzyme elevation in humans (added to statin therapy) (6% of patients).
“mild transient liver enzyme elevations occurred in 6% of patients”
Human trialadded to statin therapy24 monthsn = 172
ESC Congress 2026 abstract
Need for LLT escalation
downin humans1
1 study
Need for LLT escalation
downin humans1
Inclisiran decreases need for LLT escalation in humans (inclisiran-based therapy compared with individually optimized lipid-lowering therapy) (12.5% vs 52.8% requiring >20 mg rosuvastatin).
“By D360, 64.8% of those on inclisiran-based therapy vs 12.5% on ioLLT had ≤10 mg rosuvastatin; fewer required >20 mg (12.5% vs 52.8%; Table).”
Human trialinclisiran-based therapy compared with individually optimized lipid-lowering therapy>20 mg rosuvastatin360 days
Inclisiran helped more high-risk people reach cholesterol goals
ESC Congress 2026 abstract
Achievement of LDL-C <55 mg/dL
upin humans1RR 1.41
1 study
Achievement of LDL-C <55 mg/dL
upin humans1RR 1.41
Inclisiran increases achievement of LDL-C <55 mg/dL in humans (Ischemic HFrEF on atorvastatin 80 mg and ezetimibe 10 mg; compared with evolocumab) (91.7% versus 65.0%; RR 1.41, 95% CI 1.12–1.78; p=0.02).
“the primary endpoint was achieved by 91.7% (11/12) of patients in the Inclisiran group versus 65.0% (65/100) in the Evolocumab group”
Human trialIschemic HFrEF on atorvastatin 80 mg and ezetimibe 10 mg; compared with evolocumabsiRNA284 mg5 months75% malesn = 112
ESC Congress 2026 abstract
LDL-C goal attainment
upin humans1
1 study
LDL-C goal attainment
upin humans1
Inclisiran improves LDL-C goal attainment in humans (78.2% vs 20.3%, aOR 16.36 (95% CI 9.72 to 27.54)).
“At Day 150, a higher proportion of patients treated with inclisiran achieved their individual guideline-recommended LDL-C targets compared with BPA (78.2% vs 20.3%; adjusted odds ratio (aOR) 16.36 [95% CI 9.72 to 27.54]; P <.0001) (Figure 4A).”
Human trial150 daysn = 402
European heart journal
ApoB
downin humans1−37%
1 study
ApoB
downin humans1−37%
Inclisiran decreases ApoB in humans (elevated LDL-C, low/moderate ASCVD risk, monotherapy) (-36.84%).
“nonhigh-density lipoprotein cholesterol, -40.57%; apolipoprotein B, -36.84%”
Human trialelevated LDL-C, low/moderate ASCVD risk, monotherapy150 daysn = 207
Journal of clinical lipidology
All 36Fewer
What is inclisiran linked with?
15Studies link inclisiran with 15 measures, among them LDL-C, acute kidney injury and all-cause hospitalization.
LDL-C
downin humans1
1 study
LDL-C
downin humans1
Inclisiran is associated with LDL-C in humans (Median LDL-C reduction of 77% at day 14; baseline 138 mg/dL and day 14 31 mg/dL).
“Baseline LDL-C was 138 mg/dL and fell to 75 and 31 mg/dL at days 3 and 14 after the dose (median reductions 45% and 77%).”
HumansIschemic stroke; combined with intensified oral therapy, whose contribution cannot be isolated284 mg14 daysn = 15
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Acute kidney injury
downin humans1HR 0.62
1 study
Acute kidney injury
downin humans1HR 0.62
Inclisiran is associated with acute kidney injury in humans (10.4% vs 19.2%; HR 0.62, 95% CI 0.41–0.95).
“and acute kidney injury (10.4% vs 19.2%; HR, 0.62; 95% CI, 0.41 - 0.95; p=0.03).”
HumansMASLD and elevated cardiovascular risk; receiving statin and ezetimibe therapy; compared with no inclisiran3 yearsn = 317
AHA Scientific Sessions 2026 abstract
All-cause hospitalization
downin humans1HR 0.58
1 study
All-cause hospitalization
downin humans1HR 0.58
Inclisiran is associated with all-cause hospitalization in humans (25.6% vs 44.8%; HR 0.58, 95% CI 0.44–0.76).
“Inclisiran use was associated with lower three-year hazards of all-cause hospitalization compared with no inclisiran”
HumansMASLD and elevated cardiovascular risk; receiving statin and ezetimibe therapy; compared with no inclisiran3 yearsn = 317
AHA Scientific Sessions 2026 abstract
Mortality
downin humans1HR 0.639
1 study
Mortality
downin humans1HR 0.639
Inclisiran is associated with mortality in humans (Compared with evolocumab in patients with atherosclerotic heart disease and dyslipidemia) (HRs 0.639, 0.670, and 0.695 at 1, 3, and 5 years; not significant).
“Inclisiran showed lower mortality than evolocumab (HRs 0.639, 0.670, 0.695)”
HumansCompared with evolocumab in patients with atherosclerotic heart disease and dyslipidemia1, 3, and 5 years
AHA Scientific Sessions 2026 abstract
Major adverse cardiovascular events
downin humans1RR 0.74
1 study
Major adverse cardiovascular events
downin humans1RR 0.74
Inclisiran lowers the risk of major adverse cardiovascular events in humans (Symptomatic peripheral artery disease; versus control) (RR 0.74, 95% CI 0.63-0.87; NNT=24).
“MACE was significantly lower (RR 0.74, 95% CI 0.63-0.87; p=0.0002; NNT=24).”
ReviewSymptomatic peripheral artery disease; versus controlMedian follow-up 24 monthsn = 6,741
AHA Scientific Sessions 2026 abstract
Major adverse limb events
downin humans1RR 0.69
1 study
Major adverse limb events
downin humans1RR 0.69
Inclisiran lowers the risk of major adverse limb events in humans (Symptomatic peripheral artery disease; versus control) (RR 0.69, 95% CI 0.58-0.82; NNT=18).
“MALE was significantly reduced (RR 0.69, 95% CI 0.58-0.82; p<0.0001; NNT=18).”
ReviewSymptomatic peripheral artery disease; versus controlMedian follow-up 24 monthsn = 6,741
AHA Scientific Sessions 2026 abstract
Achievement of any LDL-C reduction
upin humans1RR 1.27
1 study
Achievement of any LDL-C reduction
upin humans1RR 1.27
Inclisiran is associated with achievement of any LDL-C reduction in humans (Hypercholesterolemia; compared with PCSK9 monoclonal antibodies) (45.9% vs 36.0%; RR 1.27, 95% CI 1.13-1.43).
“inclisiran was associated with a higher proportion of patients achieving any LDL-C reduction (45.9% vs 36.0%; RR 1.27, 95% CI 1.13-1.43; P<0.001)”
HumansHypercholesterolemia; compared with PCSK9 monoclonal antibodies90- to 365-day window after initiationn = 844
AHA Scientific Sessions 2026 abstract
LDL cholesterol
downin humans1
1 study
LDL cholesterol
downin humans1
Inclisiran is associated with LDL cholesterol in humans (LDL-C −29.5%; total cholesterol −22.6%; triglycerides −29.0%).
“LDL-C was reduced by 29.5%, total cholesterol by 22.6%, and triglycerides by 29.0% (all P < 0.01).”
Humansn = 45
Impact of inclisiran on the cardiometabolic–inflammatory index: a real-world observational study
ESC Congress 2026 abstract
Cardiometabolic inflammation index
downin humans1
1 study
Cardiometabolic inflammation index
downin humans1
Inclisiran is associated with cardiometabolic inflammation index in humans (Absolute change −0.44; 95% CI −0.63 to −0.24; −8.24%).
“Mean CTI decreased from 5.32 ± 0.70 at baseline to 4.88 ± 0.53 at follow-up”
Humansn = 45
Impact of inclisiran on the cardiometabolic–inflammatory index: a real-world observational study
ESC Congress 2026 abstract
Rehospitalization for ischemic events
downin humans1
1 study
Rehospitalization for ischemic events
downin humans1
Inclisiran is associated with rehospitalization for ischemic events in humans after two years of treatment (none reported).
“with no rehospitalizations for ischemic events”
Humansafter two years of treatmenttwo yearsn = 1
Russian Journal of Cardiology
All 15Fewer
Has inclisiran been tested in people?
7 of 51 about agingYes: 14 trials and 34 observational studies in people have been published, and 44 trials are registered.
About aging
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Phase 3Active, not recruiting
Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma
Recruiting
LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering
Phase 4Recruiting
Phase 3Completed
Phase 3Completed
Phase 3Completed
All 7Fewer
Approved
Dec 22, 2021Homozygous Familial Hypercholesterolemia, Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia
Repurposing
Phase 4Results posted3 trials
Phase 3Recruiting2 trials
Phase 4Recruiting2 trials
Phase 4Completed13 trials
Phase 3Results posted2 trials
Phase 3Recruiting2 trials
All 22Fewer
Every condition in trials
Hyperlipidemias
Phase 4Active, not recruiting9 trials
Hyperlipoproteinemia type II
Phase 3Recruiting4 trials
Familial hypercholesterolemia heterozygous
Phase 3Results posted1 trial
Readouts due
- Nov 27, 2026
Phase 4Recruiting
- Dec 30, 2026
Phase 4Active, not recruiting
- Jan 16, 2027
- Apr 28, 2027
- Apr 30, 2027
Inclisiran Effectiveness in China: a Pragmatic Randomized Trial
Phase 4Active, not recruiting
- May 10, 2027
Phase 3Active, not recruiting
All 7Fewer
Who is developing inclisiran?
2 companies: Novartis Pharmaceuticals and Shanghai Minwei Biotechnology.
Trial sponsors
Novartis Pharmaceuticals Corporation
Company25 trialsPhase 429,693 people
Company5 trialsPhase 34,192 people
Company1 trialPhase 2216 people
Azienda Ospedaliera Universitaria Federico II Di Napoli
1 trialPhase 4372 people
Seoul National University Bundang Hospital
1 trialPhase 4294 people
1 trialPhase 4130 people
University Medical Centre Ljubljana
1 trialPhase 460 people
First Affiliated Hospital of Xinjiang Medical University
1 trialPhase 440 people